/

CODX

Co-Diagnostics, Inc.Closed

1.07−0.19 −14.80%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.07 +0.47%

Open

1.24

Prev close

1.25

Day range

1.061.25

52-week range

0.906046.50

Volume

481.71K1.42×

Mkt cap

7.44M

P/E ttm

—

Fwd P/E

-1.28

EPS ttm

-26.14

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−97.71%

Price Chart

Yahoo Finance · delayed

CODXOct 13, 2026O 1.24H 1.25L 1.06C 1.07−0.18 (−14.80%)Vol 505.30K

SMA 501.19
SMA 2002.52

1Y change −90.78% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CODX Co-Diagnostics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.39%
1 month: −4.91%
3 months: −58.56%
6 months: −22.83%
Year to date: −78.99%
1 year: −90.78%

Valuation & ownership

Market cap: 7.44M
Enterprise value: 4.81M
P/E (ttm): —
Forward P/E: -1.28
PEG ratio: —
Price / book: 0.41
Price / sales (ttm): 10.31
EV / EBITDA: -0.17
EPS (ttm): -26.14
EPS (forward): -0.8300
Beta (5y monthly): 2.90
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 6.98M
Float: 6.13M
Short % of float: 6.10%
Short ratio (days): 1.73
Held by insiders: 2.07%
Held by institutions: 10.53%
Avg volume (3m): 339.85K
50-day average: 1.20
200-day average: 2.55
52-week change: −90.78%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 43.8
vs 50-day SMA: −10.85%
vs 200-day SMA: −57.73%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 9.59%
Realised vol (20d, ann.): 112.0%
From 52-week high: −97.71%
From 52-week low: +17.55%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

4.00

+275.59% implied

Low 4.00Median 4.00High 4.00

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Co-Diagnostics, Inc.

Yahoo Finance profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Sector: Healthcare
Industry: Medical Devices
Employees: 115
Headquarters: Salt Lake City, UT, United States
Website: co-dx.com
Officers: Mr. Dwight H. Egan Chairman, CEO & President
Mr. Richard David Abbott President
Mr. Dan Bohrer CPA Executive VP of Finance & Accounting and Principal Financial & Accounting Officer

SEAS

Seasonality · CODX

2017–2026 · monthly returns

Strongest month Jan +38.20%Weakest month Dec −19.69%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-53.1	-3.3	-19.1	-16.7	450.3	-63.7	-53.5	-13.9	-13.7	-0.5			−79.0%
2025	0.1	-34.1	-37.4	13.2	-27.1	9.4	-7.5	27.4	4.2	33.7	-19.3	-54.4	−77.5%
2024	-6.0	-9.6	-0.9	3.6	-9.5	19.0	-8.0	20.9	-10.1	-3.2	-26.4	-15.8	−43.6%
2023	28.6	-10.8	-48.8	-6.8	-21.0	1.8	40.5	-20.5	-14.5	0.9	10.3	12.7	−47.2%
2022	-20.5	-18.3	6.6	-28.8	14.8	11.1	16.9	-48.5	-5.0	8.1	-13.3	-16.3	−71.8%
2021	38.1	7.2	-30.7	-7.1	-8.9	2.2	22.5	6.3	-9.5	-15.6	17.4	-7.4	−4.0%
2020	264.2	305.8	-42.4	48.8	58.7	7.5	24.0	-54.6	24.7	-1.3	-12.6	-20.6	+939.1%
2019	-8.7	-8.8	-14.5	-4.7	-20.7	0.4	59.2	-16.4	-3.7	-6.8	-7.3	0.6	−39.9%
2018	9.8	-40.3	26.0	-11.9	51.0	33.8	-9.3	-7.1	-19.6	-12.2	-10.4	-28.0	−43.6%
2017								31.9	12.0	-6.9	-12.9	-47.9	−37.6%

INSD

Insider Activity · CODX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 21, 2026	Serbin Richard SDirector	Stock Award(Grant) at price 0.00 per share.	1.7K	—
May 21, 2026	Egan Dwight H.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	4.6K	—
May 21, 2026	Nelson James BDirector	Stock Award(Grant) at price 0.00 per share.	1.7K	—
May 21, 2026	Murphy Edward L.Director	Stock Award(Grant) at price 0.00 per share.	1.7K	—
May 21, 2026	Durenard Eugene ADirector	Stock Award(Grant) at price 0.00 per share.	1.7K	—
May 21, 2026	Brown Brian LeeChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	3.8K	—
May 21, 2026	Abbott Richard DavidPresident	Stock Award(Grant) at price 0.00 per share.	1.9K	—
May 21, 2026	Serbin Richard SDirector	Conversion of Exercise of derivative security at price 5.07 per share.	5.7K	$28.87K
May 21, 2026	Egan Dwight H.Chief Executive Officer	Conversion of Exercise of derivative security at price 5.07 per share.	13.8K	$69.71K
May 21, 2026	Nelson James BDirector	Conversion of Exercise of derivative security at price 5.07 per share.	5.7K	$28.87K
May 21, 2026	Murphy Edward L.Director	Conversion of Exercise of derivative security at price 5.07 per share.	5.7K	$28.87K
May 21, 2026	Durenard Eugene ADirector	Conversion of Exercise of derivative security at price 5.07 per share.	5.7K	$28.87K
May 21, 2026	Brown Brian LeeChief Financial Officer	Conversion of Exercise of derivative security at price 5.07 per share.	11.3K	$57.04K
May 21, 2026	Abbott Richard DavidPresident	Conversion of Exercise of derivative security at price 5.07 per share.	9.8K	$49.65K
Nov 20, 2025	Serbin Richard SDirector	—	57.5K	—
Nov 20, 2025	Egan Dwight H.Chief Executive Officer	—	163.3K	—
Nov 20, 2025	Nelson James BDirector	—	57.5K	—
Nov 20, 2025	Murphy Edward L.Director	—	57.5K	—
Nov 20, 2025	Durenard Eugene ADirector	—	57.5K	—
Nov 20, 2025	Brown Brian LeeChief Financial Officer	—	134.2K	—

13F

Investors Holding CODX

latest 13F filings of 29 followed managers

Investors holding CODX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$38.8K	0.00%	12.50K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CODX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CODX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Co-Diagnostics, Inc.

Seasonality · CODX

Insider Activity · CODX

Congress Trades · CODX

Investors Holding CODX

Investors Holding CODX

Congress Trades · CODX

Insider Activity · CODX

Seasonality · CODX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Co-Diagnostics, Inc.

Financial Snapshot

Earnings & Dividends

News